

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



四环医药  
*SihuanPharm*

**Sihuan Pharmaceutical Holdings Group Ltd.**

**四環醫藥控股集團有限公司**

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0460)**

## **POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 2 JUNE 2023**

At the annual general meeting (the “**AGM**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**”) held on 2 June 2023, all the proposed resolutions as set out in the notice of the AGM dated 28 April 2023 were taken by way of poll.

As at the date of the AGM, the total number of issued shares of the Company was 9,329,999,206 shares, which was the total number of shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM. There were no restrictions on any shareholders of the Company (“**Shareholders**”) casting votes on any of the proposed resolutions at the AGM. There were no shares entitling the holder to attend and abstain from voting in favour of the proposed resolutions at the AGM under Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). No Shareholder was required under the Listing Rules to abstain from voting on any of the proposed resolutions at the AGM. No party has stated its intention in the circular of the Company dated 28 April 2023 that it would vote against any proposed resolution or that it would abstain from voting at the AGM.

The Hong Kong branch share registrar of the Company, Tricor Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. All the resolutions were approved by the Shareholders. The poll results in respect of the respective resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors of the Company (the “ <b>Directors</b> ”) and auditor of the Company (the “ <b>Auditor</b> ”) for the year ended 31 December 2022.	5,524,991,761 (99.96%)	2,161,550 (0.04%)
2.	To approve the declaration and payment of a final cash dividend for the year ended 31 December 2022.	5,527,083,311 (99.99%)	70,000 (0.01%)
3.	(a) To re-elect the following retiring Directors:		
	(i) Dr. Guo Weicheng as an executive Director	5,513,143,281 (99.75%)	14,010,030 (0.25%)
	(ii) Dr. Zhang Jionglong as an executive Director	5,523,589,281 (99.94%)	3,564,030 (0.06%)
	(iii) Ms. Chen Yanling as an executive Director	5,524,347,311 (99.95%)	2,806,000 (0.05%)
	(iv) Ms. Miao Guili as an executive Director	5,521,656,611 (99.90%)	5,496,700 (0.10%)
	(v) Mr. Wang Guan as an independent non-executive Director	5,526,973,311 (99.99%)	180,000 (0.01%)
	(b) To authorize the board of Directors (the “ <b>Board</b> ”) to fix the remuneration of the Directors	5,526,539,311 (99.99%)	614,000 (0.01%)
4.	To re-appoint Ernst & Young as Auditor and authorize the Board to fix their remuneration.	5,527,083,311 (99.99%)	70,000 (0.01%)

ORDINARY RESOLUTIONS			No. of Votes (%)	
			For	Against
5.	(A)	To give a general mandate to the Directors to allot, issue and deal with additional shares not exceeding 20 per cent of the number of issued shares of the Company.	5,285,113,068 (95.62%)	242,040,243 (4.38%)
	(B)	To give a general mandate to the Directors to repurchase shares not exceeding 10 per cent of the number of issued shares of the Company.	5,527,083,311 (99.99%)	70,000 (0.01%)
	(C)	To extend the authority given to the Directors pursuant to ordinary resolution no. 5(A) to issue shares by adding to the number of issued shares of the Company the number of shares repurchased under ordinary resolution no. 5(B).	5,285,316,010 (95.62%)	241,837,301 (4.38%)

As more than 50% of votes were casted in favour of the resolutions numbered 1 to 5, all the above resolutions were duly passed as ordinary resolutions.

SPECIAL RESOLUTION			No. of Votes (%)	
			For	Against
6.		To approve the amendments to the existing bye-laws of the Company and adopt the amended and restated bye-laws of the Company.	5,130,951,038 (92.83%)	396,202,273 (7.17%)

As more than 75% of votes were casted in favour of the resolution numbered 6, the above resolution was duly passed as a special resolution.

All Directors attended the AGM.

By order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

China, 2 June 2023

*As at the date of this announcement, the executive Directors are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive Directors are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.*